Buy online Megabrom Eye Drop From USA

megabrom_eye_drop_0.09_-_5ml

About Megabrom Eye Drop

Megabrom Eye Drop reduces pain in the eyes as well as swelling around them, in patients who have just undergone cataract surgery. Known to be a NSAID (nonsteroidal anti-inflammatory drug), it is available in the form of an eye drop. The drug functions by preventing prostaglandin production. This is a drug which causes swelling and pain around the eyes.

 

What are the uses of Eye Drop?

Megabrom Drops use for the treatment of Eye pain, Eye inflammation, Postoperative inflammation and reduction of ocular pain and other conditions.

The complete list of uses and indications for Megabrom S Drops is as follows:

Eye pain

Eye inflammation

Postoperative inflammation and reduction of ocular pain

 

How to use Megabrom Eye Drop

Megabrom Eye Drop  for external use only.Take it in the dose and duration as advised by your doctor. Check the label for directions before use. Hold the dropper close to the eye/ear without touching it.

 How use Megabrom Eye Drop – Gently squeeze the dropper and place the medicine inside the lower eyelid or ear. Wipe off extra liquid.

How Megabrom Eye Drop works

Megabrom Eye Drop is a non-steroidal anti-inflammatory drug (NSAID).

How work Megabrom Eye Drop –  It works by stopping the release of certain natural substances in the eye that are responsible for pain and inflammation (redness and swelling).

 

Side effects

Major & minor side effects of  Megabrom Eye Drops

Burning and stinging of eye

Red or itchy eyes

Headache

Eye pain

Eye discharge

Visual disturbances

 

Dosage

Instruction for Dosage of Megabrom Eye Drop

Missed Dose

Administer the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.

 

Warnings

Warnings for special population

 

Pregnancy – 

Megabrom Eye Drop  is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before using this medicine.

Breast-feeding

Megabrom Eye Drop is not recommended for use in breastfeeding women unless necessary. All the risks and benefits should be discussed with the doctor before using this medicine. If the medicine is used, the infant should be monitored closely for any adverse effects.

General warnings

 

Contact lens

Megabrom Eye Drop is not recommended for use if you are wearing soft contact lenses in your eyes. The lens should be removed prior to administration of the eye drops and can be reinserted 10 to 15 minutes post administration.

Sulfite allergic reactions

Megabrom Eye Drop contains sodium sulfite and it may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in some patients. Report any unusual symptoms to the doctor immediately. Appropriate corrective measures or replacement with a suitable alternative may be required based on the clinical condition of the patient.

Use in pediatrics

Megabrom Eye Drop is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

Slow or delayed healing

Megabrom Eye Drop  may slow or delay healing in some patients. Report any lack of improvement to the doctor immediately. Replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

Increased bleeding time –

Megabrom Eye Drop should be used with caution in patients with a known history of bleeding disorders due to the increased risk of excessive bleeding. Report any unusual symptoms to the doctor immediately. Close monitoring of bleeding time, appropriate corrective measures, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

 

For More information to visit our Site Medypharma.com

Have any Question or Comment?

Leave a Reply

Your email address will not be published. Required fields are marked *